OTR Global downgraded its view of Edwards Lifesciences to Mixed from Positive, noting that based on its checks 2023 TAVR procedure growth forecasts have slipped among U.S. cardiology practitioners.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EW:
- Edwards Lifesciences price target raised to $77 from $75 at Baird
- Edwards Lifesciences price target lowered by $7 at Barclays, here’s why
- Edwards Lifesciences approves $1B of additional share repurchase authorization
- Edwards Lifesciences sees FY24 adjusted EPS $2.70-$2.80, consensus $2.80
- Edwards Lifesciences backs FY23 adjusted EPS view $2.47-$2.53, consensus $2.51
